arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

CytomX Therapeutics, Inc.

CTMX
$3.47 ▲ +0.10 (+2.81%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
50 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

CytomX Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $615.1M
Dividend Yield
Revenue Growth -79.9%
Op. Margin -191.8%
ROIC -6.2%
FCF / Share $-0.14
Trailing P/E
Price / Book 1.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

50-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$10.26M
↓ -79.9%
Net Income Profit after all expenses
$-18.25M
↑ +31.2%
Operating Margin Operating profit as % of sales
-191.8%
↑ +27.5% 8th
FCF / Share Free cash flow per share
$-0.14
↑ +40.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
7
Returns
29
Cash Quality
94

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 50 quarters